Maulik Shukla

Maulik Shukla

Auto-generated profile, based on publicly available information

Maulik Shukla

Department of Energy, Argonne National Laboratory, Lemont, IL

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2016 in Scientific Reports
Verified
Journal Article
Open access
JDJames J. Davis
James J. Davis
SBSébastien Boisvert
Sébastien Boisvert
TBThomas Brettin
Thomas Brettin
RKRonald W. Kenyon
Ronald W. Kenyon
CMChunhong Mao
Chunhong Mao
RSRick Stevens
Rick Stevens
The emergence and spread of antimicrobial resistance (AMR) mechanisms in bacterial pathogens, coupled with the dwindling number of effective antibiotics, has created a global health crisis. Being able to identify the genetic mechanisms of AMR and predict the resistance phenotypes of bacterial pathogens prior to culturing could inform clinical decision-making and improve reaction time. At PATRIC (http://patricbrc.org/), we have been collecting bacterial genomes with AMR metadata for several years. In order to advance phenotype prediction and the identification of genomic regions relating to AMR, we have updated the PATRIC FTP server to enable access to genomes that are binned by their AMR phenotypes, as well as metadata including minimum inhibitory concentrations. Using this infrastructure, we custom built AdaBoost (adaptive boosting) machine learning classifiers for identifying carbapenem resistance in Acinetobacter baumannii, methicillin resistance in Staphylococcus aureus, and beta-lactam and co-trimoxazole resistance in Streptococcus pneumoniae with accuracies ranging from 88-99%. We also did this for isoniazid, kanamycin, ofloxacin, rifampicin, and streptomycin resistance in Mycobacterium tuberculosis, achieving accuracies ranging from 71-88%. This set of classifiers has been used to provide an initial framework for species-specific AMR phenotype and genomic feature prediction in the RAST and PATRIC annotation services.

18 November 2025 in Nucleic Acids Research
Verified
Journal Article
Closed access
MSMaulik Shukla
Maulik Shukla
AWAlice R Wattam
Alice R Wattam
AAAntonio Aleman
Antonio Aleman
RBRoshni Bhattacharya
Roshni Bhattacharya
NBNicole Bowers
Nicole Bowers
RSRick L Stevens
Rick L Stevens
The Bacterial and Viral Bioinformatics Resource Center (BV-BRC; https://www.bv-brc.org) is a comprehensive resource supporting research on bacterial and viral pathogens. It currently hosts over 14 million publicly available genomes and 33 high-throughput bioinformatic analysis services with numerous visual analytic tools allowing researchers to analyze their private data, generate comparisons with public data, and share data and results with colleagues. In recent years, the BV-BRC has added several new analysis services to support rapid comparative genomics and epidemiological analysis, viral genome assembly and annotation, viral subspecies classification, wastewater analysis, and molecular docking. In addition, several existing services have been updated to incorporate state-of-the-art tools, including assembly, annotation, taxonomic classification, metagenomic read mapping, and RNA-seq analysis. A new tool, called BV-BRC Copilot, provides an AI-powered natural-language interface that combines large language models with retrieval-augmented generation to guide users through data exploration, analysis workflows, and knowledge integration. With expanded outbreak tracking pages, training and educator engagement, and continued development of novel AI-driven analytics, BV-BRC continues to provide a unified resource to meet the evolving needs of the global research community.

8 March 2014 in 3 Biotech
Verified
Journal Article
Open access
PDF file
JFJosé P. Faria
José P. Faria
JEJanaka N. Edirisinghe
Janaka N. Edirisinghe
JDJames J. Davis
James J. Davis
TDTerrence Disz
Terrence Disz
AHAnna Hausmann
Anna Hausmann
AWAlice R. Wattam
Alice R. Wattam
For many scientific applications, it is highly desirable to be able to compare metabolic models of closely related genomes. In this short report, we attempt to raise awareness to the fact that taking annotated genomes from public repositories and using them for metabolic model reconstructions is far from being trivial due to annotation inconsistencies. We are proposing a protocol for comparative analysis of metabolic models on closely related genomes, using fifteen strains of genus Brucella, which contains pathogens of both humans and livestock. This study lead to the identification and subsequent correction of inconsistent annotations in the SEED database, as well as the identification of 31 biochemical reactions that are common to Brucella, which are not originally identified by automated metabolic reconstructions. We are currently implementing this protocol for improving automated annotations within the SEED database and these improvements have been propagated into PATRIC, Model-SEED, KBase and RAST. This method is an enabling step for the future creation of consistent annotation systems and high-quality model reconstructions that will support in predicting accurate phenotypes such as pathogenicity, media requirements or type of respiration.

12 November 2023
Verified
Conference Paper
Open access
ONOleksandr Narykov
Oleksandr Narykov
YZYitan Zhu
Yitan Zhu
TBThomas Brettin
Thomas Brettin
YEYvonne Evrard
Yvonne Evrard
APAlexander Partin
Alexander Partin
RSRick Stevens
Rick Stevens
This work studies a particular setting for regression problems – tasks with complex combinatorial data space where samples can be divided into distinct groups. Anti-cancer drug response prediction is a perfect example of this setting, in which each sample includes cancer biological features and drug chemical information. Many existing works of pan-drug and pan-cancer response modeling treat different combinations of drugs and cancers as individual samples. A potential problem in these works is that a model may be heavily influenced and biased toward overrepresented drugs and cancers. Our work develops a method to solve this issue by adjusting the model training process in a deep learning framework. In the drug response prediction field, the performance of pan-cancer pan-drug models is commonly evaluated on a holdout test set through cross-validation (CV) using performance metrics like the coefficient of determination (R2) and the mean squared error (MSE). However, drug response prediction can be viewed as a multi-objective optimization task, attempting to maximize the prediction performance over different drugs and cancers. We consider the performance for each drug as a separate objective and attempt to find a model on the corresponding Pareto front that provides balanced performances for all compounds. We propose adding an entropy-based regularization to the loss function for model training to reach this balanced state. The intuition behind it is straightforward – we minimize the MSE on all data points while encouraging the drug-specific model fitting error variability to stay as low as possible. We achieve this by grouping samples by their drug identity and computing the MSE for each group in the training batch. Then we calculate entropy over normalized group-specific losses. This value is plugged into the regularization term that incentivizes the loss function to maximize it. The maximum entropy can be achieved when the MSEs across all drugs take the same value. We investigate the regularization effect on response modeling using a drug screening dataset of Cancer Cell Line Encyclopedia (CCLE) and a state-of-the-art drug response prediction model DeepTTA [1]. We consider two CV strategies for model evaluation – random split and drug-blind split. In a random split, the testing set can share both cell lines and drugs with the training set, while in a drug-blind split, a drug can not appear simultaneously in both the training and testing sets. We perform 10-fold CV analyses and evaluate the model performance using R2. For the random split, we see that adding the entropy-based regularization leads to a marginal improvement in prediction performance, which is 0.736 without regularization versus 0.746 with regularization and a p-value of 0.130 from the pairwise t-test. Importantly, we observe a substantial improvement in the more challenging setting of drug-blind split, where the prediction performance increases from -0.128 (without regularization) to 0.168 (with regularization) with a statistically significant p-value of 0.005 from pair-wise t-test.

15 March 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
ONOleksandr Narykov
Oleksandr Narykov
YZYitan Zhu
Yitan Zhu
TBThomas Brettin
Thomas Brettin
YEYvonne A. Evrard
Yvonne A. Evrard
APAlexander Partin
Alexander Partin
RSRick L. Stevens
Rick L. Stevens
Drug response prediction (DRP) methods tackle the complex task of associating the effectiveness of small molecules with the specific genetic makeup of the patient. Anti-cancer DRP is a particularly challenging task requiring costly experiments as underlying pathogenic mechanisms are broad and associated with multiple genomic pathways. The scientific community has exerted significant efforts to generate public drug screening datasets, giving a path to various machine learning (ML) models that attempt to reason over complex data space of small compounds and biological characteristics of tumors. However, the data depth is still lacking compared to computer vision or natural language processing domains, limiting current learning capabilities. To combat this issue and increase the generalizability of the DRP models, we are exploring strategies that explicitly address the imbalance in the DRP datasets. We reframe the problem as a multi-objective optimization across multiple drugs to maximize deep learning model performance. We implement this approach by constructing Multi-Objective Optimization Regularized by Loss Entropy (MOORLE) loss function and plugging it into a Deep Learning model. We demonstrate the utility of proposed drug discovery methods and make suggestions for further potential application of the work to promote equitable outcomes in the healthcare field. Availability https://github.com/AlexandrNP/MOORLE Contact onarykov{at}anl.gov

1 June 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
APAlexander Partin
Alexander Partin
TBThomas S. Brettin
Thomas S. Brettin
YZYitan Zhu
Yitan Zhu
MSMaulik Shukla
Maulik Shukla
FXFangfang Xia
Fangfang Xia
RSRick L. Stevens
Rick L. Stevens
E13572 Background: Prediction of drug response is a critical research area in precision oncology and has been previously explored with large drug screening studies of cancer cell lines (CCLs). Patient-derived xenografts (PDXs) are an appealing platform for preclinical drug studies because the in vivo environment of PDXs helps preserve tumor heterogeneity and usually better mimics drug response of patients with cancer compared to CCLs. Methods: We investigate multimodal neural network (NN) and data augmentation for drug response prediction in PDXs. The multimodal NN learns to predict response using drug descriptors, gene expressions (GE), and histology whole-slide images (WSIs) where the multi-modality refers to tumor features only. The NN uses late integration where separate subnetworks are used to encode the input feature types before concatenation and prediction layers. Median tumor volume per treatment group is assessed relative to the control group to create a binary variable representing response. The data include twelve single-drug and 36 drug-pair treatments resulting in 2,556 single-drug and 2,203 drug-pair response values. Pathology and omics data from 487 PDXs from NCI's Patient Derived Models Repository are used as tumor feature model inputs. We explore whether the integration of WSIs with GE improves predictions as compared with models that use GE alone. We use two methods to address the limited number of response values in the dataset: 1) homogenize drug representations which allows to combine single-drug and drug-pairs into a single dataset, 2) augment drug-pair samples by switching the order of drug features which doubles the sample size of all drug-pair samples. These methods enable us to combine single-drug and drug-pair treatments which results in 6,962 responses, allowing us to train multimodal and unimodal NNs without changing architectures or the dataset. Results: Prediction performance of three unimodal NNs which use GE (um1, um2, and um3) are compared to assess the contribution of data augmentation methods. NN um1 that uses the full dataset which includes the original and the augmented drug-pair treatments as well as single-drug treatments significantly outperforms NNs (p-values < 0.01) that ignore either the augmented drug-pairs (um2) or the single-drug treatments (um3). In assessing the contribution of multimodal learning, results show that the multimodal NN (mm) outperforms both unimodal NNs that ignore either the GE (um4) or the WSIs (um1). However, the improvement of mm over um1 is not statistically significant (p-value < 0.26). Conclusions: Our results show that data augmentation and integration of histology images and GE can help improve prediction performance of drug response in PDXs.